The atmosphere at the recent American Heart Association annual meeting was defined by a series of high profile neutral findings, leaving many in attendance wondering if established medical norms were shifting. Among the most discussed presentations was the STREAM trial, a study focusing on older adults without a prior history of heart attack or stroke. On the surface, the results seemed to suggest that these patients could stop taking their statins without seeing any significant difference in health outcomes compared to those who remained on the medication.
However, Dr. Vishal Khetpal, a preventive cardiologist and assistant professor at Northwestern University Feinberg School of Medicine, noticed something troubling when he looked closer at the actual data projections. While the study was framed as a noninferiority trial designed to see if stopping the drug was essentially as safe as continuing it, Khetpal observed that the visual curves showing patient outcomes actually diverged. In plain terms, this meant that while the result met a technical statistical threshold for noninferiority, it did not mean there was no difference between the two groups.
According to Khetpal’s analysis, those who were randomized to stop their statins actually fared worse than those who kept taking them. This discrepancy creates a confusing narrative where a study labeled as neutral might actually be signaling harm. The concern is serious enough that even the trial’s own data safety monitoring board recommended that participants who had ceased their medication consult with their physicians about starting it again.
For clinicians like Khetpal, this serves as a cautionary tale about how clinical trials are reported versus what they actually reveal. The gap between a technical finding of noninferiority and real world patient risk suggests that deprescribing statins may not be as benign as some initial interpretations of the STREAM trial imply. As physicians navigate these complex datasets, the priority remains ensuring that patients aren’t inadvertently stripped of protective therapies based on an overly optimistic reading of the numbers.
